Danaher

For decades, scientific progress has followed a familiar pattern: generate a hypothesis, run experiments, analyze results, repeat. But what if researchers could move more seamlessly between prediction and experimental evidence? That's the opportunity emerging at the intersection of AI, automation and scientific instrumentation. Today, Danaher announced a collaboration with NVIDIA Healthcare to help advance autonomous science by bringing together AI, accelerated computing, scientific instruments, laboratory workflows and experimental data. We're moving beyond simply making science faster by helping researchers create a continuous learning cycle where experiments inform models and models help design better experiments, accelerating the path from discovery to evidence. This is just the beginning of what may be possible when AI, experimental data and scientific expertise become more deeply connected. Read more: https://lnkd.in/e5Pk-mpx

Strong organizations do more than create career opportunities. They create environments where people can learn, connect and grow throughout different stages of life and work. Last quarter, Danaher associates came together in a variety of ways to support one another professionally and personally, creating opportunities for connection, development and community. Our Inclusion & Belonging team and Associate Resource Group (ARG) leaders helped create and strengthen those opportunities. We also continued investing in how we support our associates. The launch of the Caregivers + Friends ARG, career development opportunities through the Women + Friends ARG, and a dedicated kaizen focused on improving the associate experience globally reflect our ongoing commitment to creating an environment where people can navigate their careers while balancing the realities of life beyond work. Swipe to see some of the ways associates built connection, community, and career growth in Q3 ➡️

Scientific breakthroughs rarely come from a single technology. They happen when data, instruments, automation and scientific expertise work together in a continuous cycle of learning.   Today, we're sharing plans for Danaher's first AI-powered autonomous lab, designed to help researchers develop custom antibodies and other molecular tools up to 8x faster.   Built through collaboration across the Danaher ecosystem, the lab brings together AI, robotics and technologies from several of our businesses in a connected workflow. Every design is created, tested, verified and used to inform the next, helping researchers move from scientific question to validated answer with greater speed and confidence.   It's an example of how we're thinking about the future of discovery: combining AI, automation and human expertise to accelerate scientific progress and help researchers tackle increasingly complex challenges.   🔗 Learn more: https://lnkd.in/eRW9vCx3

Behind every cancer diagnosis is a complex pathology workflow, where each step contributes to the quality and confidence of the answers clinicians rely on. By bringing StatLab and Leica Biosystems together, we're expanding the expertise and capabilities that support laboratories across more of that workflow, from specimen preparation through diagnosis. It's another example of how connected capabilities can help make workflows more consistent, efficient and insightful. We're can't wait to see what Leica Biosystems and StatLab will build together to help advance precision oncology.

We are delighted that today marks Julie Sawyer Montgomery’s first official day as President and Chief Executive Officer of Danaher.   Julie brings tremendous energy, ambition, and a growth mindset to the role, grounded in a deep understanding of what distinguishes Danaher: our people and the Danaher Business System, our system of continuous improvement and the culture that makes it work. Together, these strengths fuel our ambition and relentless pursuit of innovation at the speed of life. We are excited by the opportunities ahead as Danaher’s leadership positions in life sciences and diagnostics enable us to accelerate the moment scientific discovery becomes human impact. We also want to thank Rainer Blair for serving as Danaher’s CEO for the past six years. We are grateful for his leadership and the lasting impact he has made on our company. Please join us in congratulating Julie as she steps into her new role. https://lnkd.in/g8uXqD_Q

On Saturday, Danaher walked to end Alzheimer's in the city we've called home since the beginning. Associates, families and friends joined CEO Designate Julie Sawyer Montgomery on the National Mall in Washington, DC, walking in purple for the millions of people affected by Alzheimer's disease. Alzheimer's disease is a challenge no single organization can solve. Progress depends on science, care and community moving forward together. What started as a commitment from our diagnostics businesses now includes colleagues across Danaher walking in cities across the U.S. and communities around the world. As a proud sponsor of the D.C. Walk, we're walking toward a future with earlier answers and more hope for patients and families. Every step matters. 💜

Danaher is proud to announce that Shashanka Muppaneni has been promoted to Senior Vice President and Chief Strategy Officer, effective October 1, 2026. Shashanka currently serves as Group Vice President, Strategy & Business Development for Danaher Diagnostics and has been with Danaher since 2024. Earlier in his career, he was a Managing Director and Partner at Boston Consulting Group and one of its global leaders in life sciences tools and diagnostics. "Shashanka pairs sharp strategic thinking with a pragmatic, results-oriented approach, and he has already shown a strong ability to align strategy with business execution, deliver strategic M&A, and build durable partnerships across our businesses. He will be a strong partner as we accelerate Danaher's strategy and M&A agenda in the years ahead," said Julie Sawyer Montgomery, CEO Designate. Please join us in welcoming Shashanka to his new role.

Today, we are recognizing a transition in strategy and M&A leadership. Brad Gray, Senior Vice President, Strategic Development, has worked to sharpen our approach to strategy and M&A, helping focus our M&A approach on businesses Danaher can scale efficiently through DBS as the best owner, and supporting the deployment of more than $10 billion in capital. "Brad brought additional rigor and greater clarity to our strategy and M&A work that has made our company more focused," said Rainer Blair, President and Chief Executive Officer. "His contributions will continue to shape our path forward." Brad will stay on with Danaher as an advisor through March 2027.

When changes first appeared in her father's behavior, Meena Balakrishnan (she/her) and her family thought they might be a normal part of aging. "We thought it was old age. We thought it was boredom having moved to the US from India," says Meena. It wasn't until significant disorientation led to cognitive testing that they received an answer: Alzheimer's disease. By then, the disease had already advanced. During World Alzheimer's Month, Meena is sharing her family's experience as a reminder of what earlier understanding can mean for patients, loved ones, and caregivers. Earlier answers cannot change every outcome. But they can provide more time to understand, make informed decisions, access support and plan for what comes next. Learn how connected scientific ecosystems could help bring earlier answers within reach of more patients and families: https://lnkd.in/eWMTaWja

Excited to partner with Brandeis University — Career Network on a program that gives students a firsthand look at the many paths a career in health innovation can take long before graduation. Through the new Danaher x Brandeis Career Launch Program, students will gain hands-on experiences, mentorship, and exposure to opportunities across life sciences, diagnostics, and biotechnology throughout their four years at Brandeis University.